The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ifinatamab deruxtecan for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) ...

Findings showed inclacumab did not statistically significantly reduce the rate of VOCs compared with placebo after 48 weeks. Topline data were announced from a phase 3 study evaluating inclacumab, an ...

The approval was supported by data from 3 double-blind, placebo-controlled trials that included a total of 1474 patients who met the 2016 ACR criteria for diagnosis of fibromyalgia.

The approval was based on Part 1 (72 week data) of the randomized, double-blind, placebo-controlled phase 3 ESSENCE trial.

The Food and Drug Administration (FDA) has granted Orphan Drug designation to dusquetide (SGX945) for the treatment of Behçet disease, a type of vasculitis characterized by mucocutaneous symptoms (eg, ...

Imagined speech signals were weaker than attempted speech but still accurate enough to reach up to 74% recognition in real time.